Program
Lisinopril
Also written as “lisinopril”, “LP-003 Injection” and “LP-005 Injection”.
Its studies are mostly in Hypertension · Chronic Urticaria · Hemoglobinuria, Paroxysmal · Fasting · Rhinitis, Allergic, Seasonal, led by 10 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Longbio Pharma | 138 open or running | phase 3since Dec 5, 2025 | Jun 27, 2023 | Nov 2026phase 1 · NCT06604949 |
| GlaxoSmithKline | 60 open or running | phase 3since Apr 13, 2005 | Apr 13, 2005 | none ahead |
| Novartis | 60 open or running | phase 4since Sep 12, 2005 | Sep 10, 2005 | none ahead |
| IPCA Laboratories | 40 open or running | phase 1since Nov 5, 2012 | Nov 5, 2012 | none ahead |
| Longbio Pharma (Suzhou) | 33 open or running | phase 2since Apr 23, 2026 | Apr 23, 2026 | Jul 16, 2027phase 2 · NCT07816432 |
| Par Health | 20 open or running | phase 1since Apr 1, 2008 | Apr 1, 2008 | none ahead |
| Ascension Health | 10 open or running | phase 4since Jan 2, 2018 | Jan 2, 2018 | none ahead |
| Dexa Medica Group | 10 open or running | no phasesince Sep 1, 2013 | Sep 1, 2013 | none ahead |
| Intarcia Therapeutics | 10 open or running | phase 1since Dec 21, 2015 | Dec 21, 2015 | none ahead |
| Pharmtechnology | 10 open or running | phase 1since Sep 20, 2021 | Sep 20, 2021 | none ahead |
Also a collaborator on its studies: pharmakinetics-laboratories-inc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 21 studies since Apr 13, 2005.
- Sep 20, 2021Pharmtechnology's first study: phase 1 study in BioequivalenceNew to PharmtechnologyPharmtechnology · NCT05061901 · 38 enrolled · Russian Federation
- Jun 27, 2023Longbio Pharma's first study: phase 2 study in Rhinitis, Allergic, SeasonalNew to Longbio PharmaLongbio Pharma · NCT06046391 · 180 enrolled · China
- Jan 18, 2024Phase 2 study in Chronic UrticariaLongbio Pharma · NCT06228560 · 202 enrolled · China
- Feb 3, 20243 phase 1 studiesLongbio Pharma · NCT06294301, NCT06294288, NCT06294275
- Sep 14, 2024Phase 1 study in Chronic UrticariaLongbio Pharma · NCT06604949 · 12 enrolled · China
- Aug 15, 2025Phase 2 study in Allergic DiseasesLongbio Pharma · NCT07148557 · 6 enrolled · China
- Sep 30, 2025Phase 2 study in Hemoglobinuria, ParoxysmalLongbio Pharma · NCT07212426 · 30 enrolled · China
- Nov 24, 2025Phase 2 study in Hemoglobinuria, ParoxysmalLongbio Pharma · NCT07266155 · 30 planned · China
- Dec 5, 2025Phase 3 study in Rhinitis, Allergic, SeasonalPhase 3 reachedLongbio Pharma · NCT07291284 · 546 enrolled · China
- Dec 11, 20252 phase 2 studiesLongbio Pharma · NCT07342803, NCT07313917
- Jan 15, 2026Phase 2 study in Complement-mediated Renal DiseasesLongbio Pharma · NCT07363265 · 46 planned · China
- Apr 23, 2026Longbio Pharma (Suzhou)'s first study: phase 2 study in PeriodontitisNew to Longbio Pharma (Suzhou)Longbio Pharma (Suzhou) · NCT07603713 · 100 planned · China
- Aug 14, 2026Phase 2 study in Peanut HypersensitivityLongbio Pharma (Suzhou) · NCT07785063 · 80 planned · United States, Australia, Canada and more
- Sep 7, 2026Phase 2 study in Food HypersensitivityLongbio Pharma (Suzhou) · NCT07816432 · 12 planned · China
Ahead
- Nov 2026Primary completion: phase 1 study in Chronic UrticariaLongbio Pharma · NCT06604949
- Nov 12, 2026Primary completion: phase 2 study in PeriodontitisLongbio Pharma (Suzhou) · NCT07603713
- Feb 28, 2027Primary completion: phase 2 study in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Longbio Pharma · NCT07313917
- Jul 16, 2027Primary completion: phase 2 study in Food HypersensitivityLongbio Pharma (Suzhou) · NCT07816432
TargetBeta
“An orally bioavailable, long-acting angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity”NCIt, by rule
“Angiotensin-converting enzyme inhibitor”ChEMBL 37, by rule
Studies
All 38 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07816432Food Hypersensitivity · China | 2 | Not yet recruiting | Longbio Pharma (Suzhou) | Jul 16, 2027 | 12 |
| NCT07785063Peanut Hypersensitivity · United States, Australia, Canada and more | 2 | Not yet recruiting | Longbio Pharma (Suzhou) | May 2029 | 80 |
| NCT07603713Periodontitis · China | 2 | Not yet recruiting | Longbio Pharma (Suzhou) | Nov 12, 2026 | 100 |
| NCT07363265Complement-mediated Renal Diseases · China | 2 | Not yet recruiting | Longbio Pharma | Aug 2, 2028 | 46 |
| NCT07313917Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) · China | 2 | Not yet recruiting | Longbio Pharma | Feb 28, 2027 | 150 |
| NCT07342803Allergic Asthma · China | 2 | Recruiting | Longbio Pharma | Dec 28, 2027 | 200 |
| NCT07291284Rhinitis, Allergic, Seasonal · China | 3 | Active, not recruiting | Longbio Pharma | Mar 31, 2026 | 546 |
| NCT07266155Hemoglobinuria, Paroxysmal · China | 2 | Not yet recruiting | Longbio Pharma | Dec 30, 2027 | 30 |
| NCT07212426Hemoglobinuria, Paroxysmal · China | 2 | Active, not recruiting | Longbio Pharma | May 6, 2026 | 30 |
| NCT07148557Allergic Diseases · China | 2 | Active, not recruiting | Longbio Pharma | May 31, 2026 | 6 |
| NCT06604949Chronic Urticaria · China | 1 | Active, not recruiting | Longbio Pharma | Nov 2026 | 12 |
| NCT06294288Chronic Urticaria · China | 1 | Completed | Longbio Pharma | Mar 4, 2024 | 60 |
| NCT06294275Myelodysplastic Syndromes · China | 1 | Completed | Longbio Pharma | Aug 16, 2023 | 68 |
| NCT06294301Hemoglobinuria, Paroxysmal · China | 1 | Completed | Longbio Pharma | Aug 31, 2024 | 68 |
| NCT06228560Chronic Urticaria · China | 2 | Completed | Longbio Pharma | Apr 17, 2025 | 202 |
| NCT06046391Rhinitis, Allergic, Seasonal · China | 2 | Completed | Longbio Pharma | Oct 19, 2023 | 180 |
| NCT05061901Bioequivalence · Russian Federation | 1 | Completed | Pharmtechnology | Nov 6, 2021 | 38 |
| NCT03392740Heart Failure, Systolic · United States | 4 | Withdrawn | Ascension Health | Dec 15, 2018 | 0 |
| NCT02641899Healthy · United States | 1 | Completed | Intarcia Therapeutics | Mar 2016 | 33 |
| NCT01936012Healthy · Indonesia | – | Completed | Dexa Medica Group | Feb 2013 | 34 |
| NCT01831700Fasting · India | 1 | Completed | IPCA Laboratories | Oct 2012 | 48 |
| NCT01827878Lecithin Cholesterol Acyltransferase Deficiency · India | 1 | Completed | IPCA Laboratories | Oct 2012 | 48 |
| NCT01735344Lecithin Cholesterol Acyltransferase Deficiency · India | 1 | Completed | IPCA Laboratories | Aug 2012 | 40 |
| NCT01735318Fasting · India | 1 | Completed | IPCA Laboratories | Aug 2012 | 40 |
| NCT00883506Hypertension | 1 | Completed | Novartis | Jun 2000 | 24 |
| NCT00883064Hypertension | 1 | Completed | Novartis | Apr 2000 | 32 |
| NCT01380431Lecithin Cholesterol Acyltransferase Deficiency · United States | 1 | Completed | Par Health | Oct 1999 | 18 |
| NCT01375244Fasting · United States | 1 | Completed | Par Health | Oct 1999 | 36 |
| NCT00552708Hypertension · United States | 1 | Completed | GlaxoSmithKline | Dec 2007 | 55 |
| NCT00557128Hypertension · United States | 1 | Completed | GlaxoSmithKline | Dec 2007 | 24 |
| NCT00549510Hypertension · United States | 1 | Completed | GlaxoSmithKline | Dec 2007 | 29 |
| NCT00508365Hypertension · United States | 1 | Completed | GlaxoSmithKline | Jun 3, 2008 | 62 |
| NCT00347360Hypertension · United States | 3 | Completed | GlaxoSmithKline | Apr 2008 | 654 |
| NCT00241124Hypertension · Germany | 4 | Completed | Novartis | Jun 2005 | 1,099 |
| NCT00171600Hypertension · Switzerland | 4 | Terminated | Novartis | Jan 2007 | 54 |
| NCT00171574Hypertension · Switzerland | 4 | Completed | Novartis | Jul 2006 | 124 |
| NCT00171067Hypertension · Germany, Switzerland | 3 | Completed | Novartis | May 2007 | 134 |
| NCT00108082Hypertrophy, Left Ventricular · United States | 3 | Completed | GlaxoSmithKline | Aug 2008 | 287 |
How it is read
Names in the registry
- “Lisinopril”, 10 entries
- “lisinopril”, 5 entries
- “LP-003 Injection”, 4 entries
- “LP-005 Injection”, 4 entries
- “LP-003”, 2 entries
Codes read as this program: LP003, LP005, LP001.
Conditions, from the studies’ own filings
- Hypertension, 12 studies
- Chronic Urticaria, 3 studies
- Hemoglobinuria, Paroxysmal, 3 studies
- Fasting, 3 studies
- Rhinitis, Allergic, Seasonal, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.